Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-10-22
2011-11-15
Lucas, Zachariah (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387500, C530S388100, C530S388200, C530S388230, C530S350000, C530S389100
Reexamination Certificate
active
08058400
ABSTRACT:
The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.
REFERENCES:
patent: 5989552 (1999-11-01), McKenzie et al.
patent: 6548275 (2003-04-01), Goldenberg
patent: 6605279 (2003-08-01), Freeman et al.
patent: 7148329 (2006-12-01), Figdor et al.
patent: 7285642 (2007-10-01), Figdor et al.
patent: 2003/0134297 (2003-07-01), Olson et al.
patent: 2003/0232745 (2003-12-01), Olson et al.
patent: WO-9301820 (1993-02-01), None
patent: WO-95/32734 (1995-12-01), None
patent: WO-9623882 (1996-08-01), None
patent: WO-9802456 (1998-01-01), None
patent: WO-9802456 (1998-01-01), None
patent: WO-9828332 (1998-07-01), None
patent: WO-9828332 (1998-07-01), None
patent: WO-9841633 (1998-09-01), None
patent: WO-9849306 (1998-11-01), None
patent: WO-9855508 (1998-12-01), None
patent: WO-9855508 (1998-12-01), None
patent: WO-00/63251 (2000-10-01), None
patent: WO-02/50119 (2002-06-01), None
Bakker et al. J Exp Med. Mar. 1, 1994;179(3):1005-9.
Tacken et al. Effective induction of naïve and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood, 2005, 106(4): 1278-1285.
Srivastava et al. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev. Vaccines. 3(4) Suppl. 33-52 (2004).
Cohen. Is an Effective HIV Vaccine Feasible. Science. vol. 30. p. 99 (2005).
Sausville et al. (Cancer Research, 2006, vol. 66, pp. 3351-3354).
Johnson et al. (British J. of Cancer, 2001, 84(10):1424-1431).
Ahsan et al., Immunopathogenesis of Human Immunodeficiency Virus. Seminars in Nephrology, vol. 18, No. 4, pp. 422-435 (1998).
Fè d'Ostiani, C., et al., “Dendritic Cells Discriminate between Yeasts and Hyphae of the Fungus Candida albicans: Implications for Initiation of T Helper Cell Immunity In Vitro and In Vivo,” J. Exp. Med., 191(10):1661-1673 (2000).
Forsyth, C. B., et al., “Interaction of the Fungal Pathogen Candida albicans with Integrin CD11b/CD18: Recognition by the I Domain Is Modulated by the Lectin-Like Domain and the CD18 Subunit,” The Journal of Immunology, 161:6198-6205 (1998).
Fumero et al., Immunosuppressive drugs as an adjuvant to HIV treatment. Journal of Antimicrobial Chemotherapy vol. 53, pp. 415-417 (2004).
Genbank Accession No. AB015629 including updates of Apr. 17, 1999; Apr. 20, 1999; Apr. 20, 1999 (later time); Jul. 26, 2001; and Jul. 23, 2002.
Hong et al., “Human Immunodeficiency Virus Envelope (gp120) Binding to DC-SIGN and Primary Dendritic Cells Is Carbohydrate Dependent but Does Not Involve 2G12 or Cyanovirin Binding Sites: Implications for Structural Analyses of gp120-DC-SIGN Binding,” Journal of Virology, 12855-12865 (2002).
Jameson et al., “Expression of DC-SIGN by Dendritic Cells of Intestinal and Genital Mucosae in Humans and Rhesus Macaques,” Journal of Virology, 76:1866-1875 (2002).
Marth, T., et al., “Regulation of Interleukin-12 by Complement Receptor 3 Signaling,” The Journal of Experimental Medicine, 185(11):1987-1995 (1997).
Mitchell et al., “A Novel Mechanism of Carbohydrate Recognition by the C-type Lectins DC-SIGN and DC-SIGNR,” The Journal of Biological Chemistry, 276:28939-28945 (2001).
Murdoch et al., Immune reconstitution inflammatory syndrome (IRIS): review of common infections manifestations and treatment options. AIDS Research and Therapy 4:9 (2007)
Netea, M. G., et al., “Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors,” The Journal of Clinical Investigation 116(6):1642-1650 (2006).
Rosati et al., Cytokine Response to Inactivated Candida albicans in Mice. Cell. Immunol., 162:256-264 (1995).
Stephen Smith. The patogenesis of HIV infection: stupid may not be so dumb after all. Retrovirology 3:60 (2006).
Soilleux, E.J., et al., “Cutting Edge: DC-SIGN; a Related Gene, DC-SIGNR; and CD23 Form a Cluster on 19p.13,1,2,” The Journal of Immunology, 165:2397-2942 (2000).
Szabo, I., et al., “Modulation of Macrophage Phagocytic Activity by Cell Wall Components of Candida albicans,” Cellular Immunology, 164:182-188 (1995).
Vazeux et al., “Cloning and Characterization of a New Intercellular Adhesion Molecule ICAM-R,” Nature, 360:485-488, 1992.
Wu et al., “Functional Evaluation of DC-SIGN Monoclonal Antibodies Reveals DC-SIGN Interactions with ICAM-3 Do Not Promote Human Immunodeficiency Virus Type I Transmission,” J. Virol., 76(12):5905-5914 (2002).
Andre et al.,Journal of Virology, 72(2), pp. 1497-1503 (1998).
Baribaud, Frederic, et al., “Functional and Antigenic Characterization of Human, Rhesus Macaque, Pigtailed Macaque, and Murine DC-SIGN,”Journal of Virology, 75(21), pp. 10281-10289 (2001).
Berkower, I., et al., “Chimeric HIV-1 Envelope GP120-Hepatitis B Core Antigen (HbcAg) Fusion Proteins For HIV-1 Vaccines,” FASEB Journal, 10(6):A10282 (1996).
Biosis Database, PREV 197866028654 & Kataoka et al.,Cancer Research, 38(5), pp. 1202-1207 (1987).
Cohen,Science, 287, p. 1567 (2000).
Curtis, BM, et al., “Sequence and Expression of a Membrane-Associated C-type Lectin that Exhibits CD4-Independent Binding of Human Immunodeficiency Virus Envelope Glycoprotein GP 120,” Proc. Natl. Acad. Sci. USA 89:8356-8360 (1992).
Eck J., et al., “Cloning of the Mistletoe Lectin Gene and Characterization of the Recombinant A-Chain,” European Journal of Biochemistry, 264:775-784 (1999).
Engering, Anneke, et al., “The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells,”J. of Immun., 168, pp. 2118-2126 (2000).
FDA Approves Second Indication for Monolclonal Antibody, Jun. 28, 1993, printed on Nov. 12, 2004 from http://www.fda.gov/bbs/topics/ANSWERS/ANS00506.html, Jun. 28, 1993.
Feinberg, Hadar, et al., “Structural Basis for Selective Recognition of Oligosaccharides by DC-SIGN and SC-SIGNR,”Science, 294, pp. 2163-2166 (2001) (with Supplementary Material published electronically on theSciencewebsite, 6 pgs.).
Geijtenbeek, et al., “Identification of Different Binding Sites in the Dendritic Cell-Specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1,”J. Biol. Chem., 227(13), pp. 11314-11320 (2002).
Geijtenbeek, Teunis, B.H., et al., “Identification of DC-SIGN, a Novel Dendritic Cell-Specific ICAM-3 Receptor that Supports Primary Immune Responses,”Cell, pp. 575-585 (2000).
Geijtenbeek, Teunis, B.H., et al.,Cell, pp. 587-597 (2000).
Gruber, Andreas, et al., “Functional Aspects of Binding of Monoclonal Antibody DCN46 to DC-SIGN on Dendritic Cells,”Immunology Letters, 84, pp. 103-108 (2002).
Human CD209: anti-Human CD209 (DC-SIGN) antibody, eBioscience, http://www.ebioscience.com/ebioscience/specs/antibody—14/14-2099.htm, Jan. 5, 2004.
Janeway, Charles, A., Jr., et al.,Immunobiology, (5th ed.), Garland Publishing, New York, p. 691 (2001).
Kataoka et al., “Potentiation of Concanavalin A-bound L1210 Vaccine in Vivo by Chemotherapeutic Agents,” Cancer Research, 38:1202-1207 (1978).
Kn
Figdor Carl Gustav
Geijtenbeek Teunis Bernard H.
Kooyk Yvette Van
Torensma Ruurd
Horning Michelle S
Katholieke Universiteit Nijmegen
Lucas Zachariah
Ropes & Gray LLP
LandOfFree
Composition and method for modulating dendritic cell-t cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for modulating dendritic cell-t cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for modulating dendritic cell-t cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4269281